Cassava reports q2 2025 financials results and provides business update

Austin, texas, aug. 14, 2025 (globe newswire) -- cassava sciences, inc. (nasdaq: sava, “cassava”, the “company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (cns) disorders such as tuberous sclerosis complex (tsc)-related epilepsy, today reported financial results for the second quarter ended june 30, 2025 and provided a business update.
SAVA Ratings Summary
SAVA Quant Ranking